The Corticosteroid Dilemma in Neonatal Care
For the tiniest patients in the neonatal intensive care unit (NICU), the first few weeks of life are a high-stakes battle for lung development. Bronchopulmonary dysplasia (BPD) remains a persistent threat to these extremely preterm infants, often acting as a primary driver of long-term respiratory morbidity. Because inflammation is the engine behind BPD, doctors have long turned to corticosteroids to help these infants transition off ventilators. However, determining which steroid provides the safest and most effective path forward has remained a subject of intense clinical debate.
A recent retrospective exploratory study published in Cureus sheds light on this uncertainty by comparing two common agents: hydrocortisone and dexamethasone. Researchers reviewed records from a tertiary-care NICU in western India, tracking 37 neonates born at or before 34 weeks of gestation who required respiratory support during their second week of life. The study sought to see if one drug held a clear edge in preventing death or BPD at 36 weeks postmenstrual age (PMA).
The data revealed that for these vulnerable infants, there was no statistically significant difference between the two treatments regarding their primary endpoint. The composite of death or BPD at 36 weeks PMA occurred in 22.2% of the hydrocortisone group compared to 10.5% of the dexamethasone group, a difference that did not reach statistical significance. When looking at secondary outcomes, such as weaning from oxygen support or the frequency of short-term adverse events, the two groups remained remarkably similar.
While the dexamethasone group showed a shorter duration of ventilation—15.8 days versus 19.1 days—the authors noted that this finding lost its significance after applying a Bonferroni correction for multiple comparisons. The duration of hospital stays did not differ meaningfully between the two cohorts. The researchers emphasized that because this was a retrospective, non-randomized study, it cannot be used to infer equivalence or superiority for either drug.
The wide confidence interval around the primary outcome is compatible with clinically important differences in either direction, so these findings are hypothesis-generating and require confirmation in adequately powered randomized trials with long-term neurodevelopmental follow-up.
The Weight of Clinical History
The choice of corticosteroid is not merely a matter of convenience; it carries significant historical baggage.
The reality for clinicians is that the ideal strategy for infants still dependent on respiratory support after the first week remains unsettled. This is particularly true in resource-constrained settings where protocols may vary based on local availability or the specific clinical judgment of the attending neonatologist. As noted in the Cureus findings, the lack of a standardized protocol at the study site highlights a significant challenge in neonatal research: confounding by indication, where the physician’s choice of drug might be influenced by the infant’s specific, unrecorded clinical needs.
Future Directions for Neonatal Research
The medical community continues to look for ways to refine these treatments. While the National Institutes of Health and platforms like PubMed Central (PMC) have modernized their search capabilities to better track this evolving body of literature—notably through updates to their article dataset distribution services throughout 2026—the fundamental questions remain clinical rather than digital. Until large-scale, randomized, and long-term studies are conducted, the use of corticosteroids during the second postnatal week will continue to be a balancing act for NICU teams worldwide.
For the families of these infants, the nuances of drug selection represent the difference between short-term stability and long-term health. The current findings serve as a reminder that even as medical technology advances, some of the most critical decisions in the nursery are still awaiting the definitive evidence required to turn best practices into universal standards.
